The Claim
Administration of apitegromab at a dose of 10 mg/kg every 4 weeks results in sustained target engagement with total latent myostatin levels reaching a plateau by week 16 in adults with overweight or obesity, demonstrating pharmacodynamic activity consistent with selective myostatin inhibition.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
When adults with overweight or obesity receive apitegromab at 10 mg/kg every four weeks, total latent myostatin levels stabilize by week 16, indicating the drug is engaging its intended biological target as designed.
See the scientific wording
Apitegromab at 10 mg/kg every 4 weeks achieves sustained target engagement with total latent myostatin levels plateauing by week 16 in adults with overweight or obesity, indicating pharmacodynamic activity consistent with its mechanism of selective myostatin inhibition.
Apitegromab attaches to inactive myostatin molecules in the blood, stopping them from turning into their active form. This prevents active myostatin from signaling muscles to stop growing and break down protein. As a result, muscle tissue stops losing mass and stabilizes, which shows the drug is working as intended.
What the research says
1 studyWhen people with extra weight got this drug every four weeks, a body signal that tells muscles to break down stopped rising after about four months — meaning the drug was successfully blocking that signal, just like it was designed to.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.